| 1 | 6792848 | Different effects of oestradiol, oestriol, oestetrol and of oestrone on human breast cancer cells (MCF-7) in long term tissue culture. | Acta Endocrinol (Copenh) | 1981 Sep |
3 |
| 2 | 28688001 | Pharmacokinetic Interactions and Safety of Coadministration of Glecaprevir and Pibrentasvir in Healthy Volunteers. | Eur J Drug Metab Pharmacokinet | 2018 Feb |
1 |
| 3 | 28951228 | Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis. | Clin Gastroenterol Hepatol | 2018 Mar |
1 |
| 4 | 29084747 | <i>In Vitro</i> Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir. | Antimicrob Agents Chemother | 2018 Jan |
5 |
| 5 | 29180522 | Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan. | Antimicrob Agents Chemother | 2018 Feb |
2 |
| 6 | 30341499 | Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment. | Eur J Clin Pharmacol | 2019 Feb |
13 |
| 7 | 30903385 | Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections. | J Gastroenterol | 2019 Oct |
1 |
| 8 | 31167814 | Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir. | J Pharmacol Exp Ther | 2019 Aug |
8 |
| 9 | 31646465 | Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study. | Adv Ther | 2019 Dec |
2 |
| 10 | 31682879 | Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial. | J Hepatol | 2020 Mar |
1 |
| 11 | 31868341 | Molecular and Structural Mechanism of Pan-Genotypic HCV NS3/4A Protease Inhibition by Glecaprevir. | ACS Chem Biol | 2020 Feb 21 |
2 |
| 12 | 32256037 | Efficacy and safety of Glecaprevir/Pibrentasvir in the treatment of mixed cryo-globulinemia due to chronic hepatitis C cirrhosis in a patient with chronic kidney disease. | Hippokratia | 2019 Jan-Mar |
1 |
| 13 | 32441299 | Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy. | Biosci Rep | 2020 Jun 26 |
2 |
| 14 | 33168456 | Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach. | J Infect Public Health | 2020 Dec |
1 |
| 15 | 33430709 | Exploring of paritaprevir and glecaprevir resistance due to A156T mutation of HCV NS3/4A protease: molecular dynamics simulation study. | J Biomol Struct Dyn | 2021 Jan 11 |
4 |
| 16 | 33645457 | Targeting allosteric pockets of SARS-CoV-2 main protease M<sup>pro</sup>. | J Biomol Struct Dyn | 2021 Feb 27 |
1 |
| 17 | 33906643 | Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report. | BMC Infect Dis | 2021 Apr 27 |
2 |
| 18 | 34053916 | Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials. | Gut Liver | 2021 Nov 15 |
1 |
| 19 | 34125405 | Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir. | Infect Dis Ther | 2021 Dec |
1 |
| 20 | 34407270 | Effect of glecaprevir/pibrentasvir on weight-adjusted tacrolimus trough/dose ratios in heart and kidney transplant recipients. | Transpl Infect Dis | 2021 Oct |
1 |
| 21 | 34986429 | Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery. | Comput Biol Med | 2022 Mar |
2 |
| 22 | 35024454 | Safety and efficacy of glecaprevir and pibrentasvir in north Tohoku Japanese patients with genotype 1/2 hepatitis C virus infection. | Health Sci Rep | 2022 Mar |
2 |
| 23 | 35552472 | Gadoxetic acid-enhanced magnetic resonance imaging predicts hyperbilirubinemia induced by glecaprevir during hepatitis C virus treatment. | Sci Rep | 2022 May 12 |
1 |